Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IONS
- CUSIP: 46433010
- Web: www.ionispharma.com
Capitalization:- Market Cap: $6.7 billion
- Outstanding Shares: 124,355,000
Average Prices:- 50 Day Moving Avg: $51.73
- 200 Day Moving Avg: $48.15
- 52 Week Range: $24.58 - $60.01
P/E:- Trailing P/E Ratio: 259.04
- Foreward P/E Ratio: 673.50
- P/E Growth: -8.47
Sales & Book Value:- Annual Revenue: $485.73 million
- Price / Sales: 13.79
- Book Value: $1.74 per share
- Price / Book: 30.97
Profitability:- EBIDTA: $80.88 million
- Net Margins: 5.25%
- Return on Equity: 15.52%
- Return on Assets: 2.59%
Debt:- Debt-to-Equity Ratio: 2.47%
- Current Ratio: 5.03%
- Quick Ratio: 5.00%
Misc:- Average Volume: 1.16 million shs.
- Beta: 3.13
- Short Ratio: 7.99
Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.09) EPS for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.03. The company had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. Ionis Pharmaceuticals's quarterly revenue was up 170.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.47) earnings per share. View Ionis Pharmaceuticals' Earnings History.
When will Ionis Pharmaceuticals make its next earnings announcement?
Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?
14 analysts have issued twelve-month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $18.00 to $69.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $49.46 in the next year. View Analyst Ratings for Ionis Pharmaceuticals.
What are analysts saying about Ionis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (8/8/2017)
- 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
- 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Portola Pharmaceuticals (PTLA).
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Stanley T. Crooke M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
- Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
- B. Lynne Parshall J.D., Chief Operating Officer, Corporate Secretary, Director
- Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
- C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
- Richard S. Geary Ph.D., Senior Vice President - Development
- Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
- Sarah Boyce, Chief Business Officer
- Spencer R. Berthelsen M.D., Independent Director
- Breaux B. Castleman, Independent Director
Who owns Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (7.95%), Baillie Gifford & Co. (6.01%), BB Biotech AG (5.93%), BlackRock Inc. (5.50%) and State Street Corp (2.38%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Baillie Gifford & Co., Scout Investments Inc., Artal Group S.A., BB Biotech AG, Candriam Luxembourg S.C.A., Pinnacle Associates Ltd. and Fiera Capital Corp. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Smith Asset Management Group LP, Aviva PLC, Quantitative Investment Management LLC, Capital Fund Management S.A., Nationwide Fund Advisors and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Ionis Pharmaceuticals.
How do I buy Ionis Pharmaceuticals stock?
Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $53.88.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 6 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.29) |
| Consensus Price Target: | $49.46 (8.20% downside) |
Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/17/2017 | Needham & Company LLC | Reiterated Rating | Buy | $64.00 | Low |  |
| 9/12/2017 | Stifel Nicolaus | Reiterated Rating | Hold | | Low | |
| 9/6/2017 | Barclays PLC | Initiated Coverage | Equal Weight | $55.00 | Medium | |
| 8/16/2017 | Evercore ISI | Initiated Coverage | Outperform -> Outperform | $65.00 | Low | |
| 8/14/2017 | Laidlaw | Reiterated Rating | Buy | $65.00 | Low | |
| 8/14/2017 | BMO Capital Markets | Boost Price Target | Outperform | $67.00 -> $69.00 | Low | |
| 8/10/2017 | Jefferies Group LLC | Reiterated Rating | Underperform | $17.00 -> $18.00 | High | |
| 7/27/2017 | Sanford C. Bernstein | Initiated Coverage | Market Perform | $57.00 | High | |
| 5/22/2017 | Cowen and Company | Reiterated Rating | Market Perform | | Low | |
| 5/17/2017 | Leerink Swann | Reiterated Rating | Outperform | $47.00 -> $45.00 | Medium | |
| 5/10/2017 | Piper Jaffray Companies | Set Price Target | Buy | $66.00 -> $51.00 | Low | |
| 3/10/2017 | Goldman Sachs Group, Inc. (The) | Downgrade | Neutral -> Sell | $28.00 -> $25.00 | High | |
| 1/5/2017 | Janney Montgomery Scott | Set Price Target | Hold | $44.00 | N/A | |
| 11/10/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $35.00 | N/A | |
| 9/11/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 8/2/2016 | Morgan Stanley | Initiated Coverage | Equal -> Equal Weight | $37.00 -> $37.00 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.06) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.06) | ($0.09) | $93.29 million | $104.15 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.10) | $0.03 | $86.03 million | $110.30 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.20) | $0.33 | $97.47 million | $160.30 million | View | Listen | |
| 11/9/2016 | Q316 | $0.07 | $0.06 | $114.65 million | $110.90 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.52) | ($0.47) | $38.52 million | $38.50 million | View | N/A | |
| 5/4/2016 | Q116 | ($0.50) | ($0.52) | $36.21 million | $36.90 million | View | N/A | |
| 2/25/2016 | Q415 | ($0.47) | ($0.59) | $49.32 million | $51.60 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.31) | ($0.30) | $52.93 million | $49.10 million | View | N/A | |
| 8/4/2015 | Q215 | $0.29 | $0.29 | $114.93 million | $120.40 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.19) | ($0.14) | $52.74 million | $62.60 million | View | N/A | |
| 2/27/2015 | Q414 | $0.12 | $0.25 | $74.58 million | $84.90 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.20) | ($0.23) | $45.79 million | $44.10 million | View | N/A | |
| 8/4/2014 | Q214 | ($0.12) | ($0.10) | $45.60 million | $57.08 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.23) | ($0.27) | $35.12 million | $28.20 million | View | N/A | |
| 2/28/2014 | Q413 | ($0.17) | ($0.21) | $34.20 million | $42.25 million | View | N/A | |
| 11/5/2013 | Q313 | ($0.27) | ($0.21) | $19.82 million | $23.60 million | View | N/A | |
| 8/6/2013 | Q2 2013 | ($0.21) | ($0.09) | $26.76 million | $38.10 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.02) | ($0.02) | $45.24 million | $43.36 million | View | Listen | |
| 2/28/2013 | Q4 2012 | ($0.23) | ($0.03) | $15.78 million | $19.90 million | View | Listen | |
| 11/6/2012 | Q312 | ($0.26) | ($0.37) | $23.11 million | $11.60 million | View | N/A | |
| 8/6/2012 | | ($0.08) | ($0.01) | | | View | N/A | |
| 5/8/2012 | | ($0.28) | ($0.24) | | | View | N/A | |
| 2/29/2012 | | ($0.13) | ($0.20) | | | View | N/A | |
| 11/7/2011 | | ($0.20) | ($0.27) | | | View | N/A | |
| 8/4/2011 | | ($0.22) | ($0.18) | | | View | N/A | |
| 5/5/2011 | | ($0.19) | ($0.20) | | | View | N/A | |
| 2/28/2011 | | ($0.22) | ($0.14) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)2017 EPS Consensus Estimate: $0.13
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.06) | $0.16 | $0.05 |
| Q2 2017 | 2 | ($0.38) | $0.19 | ($0.10) |
| Q3 2017 | 2 | $0.07 | $0.22 | $0.15 |
| Q4 2017 | 2 | ($0.17) | $0.23 | $0.03 |
(Data provided by Zacks Investment Research)
Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ:IONS)Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 89.24%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/6/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $55.00 | $55,000.00 | |
| 7/24/2017 | C Frank Bennett | SVP | Sell | 10,000 | $59.29 | $592,900.00 | |
| 7/20/2017 | Stanley T Crooke | Chairman | Sell | 11,000 | $55.35 | $608,850.00 | |
| 7/19/2017 | Ionis Pharmaceuticals Inc | Major Shareholder | Buy | 3,125,000 | $8.00 | $25,000,000.00 | |
| 7/17/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.45 | $865,425.00 | |
| 7/3/2017 | Brett P Monia | SVP | Sell | 309 | $51.35 | $15,867.15 | |
| 7/3/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.10 | $859,650.00 | |
| 6/1/2017 | Patrick R O'neil | SVP | Sell | 70 | $48.00 | $3,360.00 | |
| 5/1/2017 | Patrick R O'neil | SVP | Sell | 650 | $48.75 | $31,687.50 | |
| 4/25/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $47.81 | $788,865.00 | |
| 4/24/2017 | Patrick R O'neil | SVP | Sell | 500 | $45.00 | $22,500.00 | |
| 4/19/2017 | Stanley T Crooke | Chairman | Sell | 5,500 | $43.25 | $237,875.00 | |
| 4/13/2017 | Stanley T Crooke | Chairman | Sell | 22,000 | $40.69 | $895,180.00 | |
| 4/12/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $40.07 | $40,070.00 | |
| 3/3/2017 | C Frank Bennett | SVP | Sell | 5,000 | $55.00 | $275,000.00 | |
| 3/1/2017 | B Lynne Parshall | COO | Sell | 4,625 | $49.26 | $227,827.50 | |
| 3/1/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $49.29 | $73,935.00 | |
| 2/6/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | |
| 1/17/2017 | B Lynne Parshall | COO | Sell | 7,246 | $46.29 | $335,417.34 | |
| 1/17/2017 | Brett P Monia | SVP | Sell | 2,502 | $46.29 | $115,817.58 | |
| 1/17/2017 | Elizabeth L Hougen | CFO | Sell | 2,273 | $46.29 | $105,217.17 | |
| 1/17/2017 | Sarah Boyce | Insider | Sell | 1,361 | $46.29 | $63,000.69 | |
| 1/17/2017 | Stanley T Crooke | CEO | Sell | 15,382 | $46.29 | $712,032.78 | |
| 1/10/2017 | Stanley T Crooke | Chairman | Sell | 13,200 | $49.25 | $650,100.00 | |
| 1/4/2017 | Stanley T Crooke | Chairman | Sell | 18,700 | $48.89 | $914,243.00 | |
| 1/3/2017 | Brett P Monia | SVP | Sell | 309 | $48.60 | $15,017.40 | |
| 12/20/2016 | Brett P Monia | SVP | Sell | 130 | $52.48 | $6,822.40 | |
| 12/15/2016 | B Lynne Parshall | COO | Sell | 4,000 | $50.00 | $200,000.00 | |
| 12/5/2016 | Elizabeth L Hougen | CFO | Sell | 2,500 | $46.05 | $115,125.00 | |
| 12/5/2016 | Patrick R O'neil | SVP | Sell | 350 | $45.00 | $15,750.00 | |
| 12/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $42.23 | $527,875.00 | |
| 11/14/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | |
| 11/11/2016 | Elizabeth L Hougen | SVP | Sell | 5,000 | $39.75 | $198,750.00 | |
| 11/7/2016 | C Frank Bennett | SVP | Sell | 5,000 | $34.00 | $170,000.00 | |
| 10/5/2016 | Stanley T Crooke | Chairman | Sell | 11,000 | $36.61 | $402,710.00 | |
| 9/27/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $36.02 | $792,440.00 | |
| 9/21/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $35.50 | $781,000.00 | |
| 9/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $29.88 | $373,500.00 | |
| 5/31/2016 | Frederick T Muto | Director | Sell | 12,500 | $22.31 | $278,875.00 | |
| 4/6/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | |
| 4/6/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $46.13 | $507,430.00 | |
| 3/31/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $40.74 | $448,140.00 | |
| 3/23/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.40 | $45,400.00 | |
| 1/19/2016 | B Lynne Parshall | COO | Sell | 5,192 | $41.46 | $215,260.32 | |
| 1/19/2016 | C Frank Bennett | SVP | Sell | 2,110 | $41.46 | $87,480.60 | |
| 1/19/2016 | Elizabeth L. Hougen | CFO | Sell | 1,899 | $41.46 | $78,732.54 | |
| 1/19/2016 | Sarah Boyce | insider | Sell | 872 | $41.46 | $36,153.12 | |
| 1/19/2016 | Stanley T. Crooke | CEO | Sell | 13,401 | $41.46 | $555,605.46 | |
| 1/5/2016 | Stanley T. Crooke | CEO | Sell | 5,500 | $62.10 | $341,550.00 | |
| 1/4/2016 | B Lynne Parshall | COO | Sell | 809 | $61.05 | $49,389.45 | |
| 1/4/2016 | Brett P. Monia | SVP | Sell | 127 | $61.00 | $7,747.00 | |
| 1/4/2016 | Stanley T. Crooke | CEO | Sell | 11,000 | $61.05 | $671,550.00 | |
| 12/16/2015 | C Frank Bennett | SVP | Sell | 7,909 | $57.41 | $454,055.69 | |
| 12/1/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $61.50 | $61,500.00 | |
| 11/11/2015 | Joseph Klein III | Director | Sell | 6,875 | $64.18 | $441,237.50 | |
| 11/10/2015 | C Frank Bennett | SVP | Sell | 5,000 | $64.00 | $320,000.00 | |
| 11/6/2015 | C Frank Bennett | SVP | Sell | 5,000 | $56.00 | $280,000.00 | |
| 11/3/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $51.95 | $51,950.00 | |
| 10/23/2015 | Stanley T. Crooke | CEO | Sell | 44,000 | $43.85 | $1,929,400.00 | |
| 10/2/2015 | B Lynne Parshall | COO | Sell | 12,436 | $40.75 | $506,767.00 | |
| 7/6/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.01 | $354,488.18 | |
| 7/6/2015 | Stanley T Crooke | CEO | Sell | 5,000 | $57.01 | $285,050.00 | |
| 7/1/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.56 | $357,908.08 | |
| 7/1/2015 | Stanley T Crooke | CEO | Sell | 6,175 | $57.56 | $355,433.00 | |
| 6/8/2015 | Brett P Monia | SVP | Sell | 7,600 | $66.22 | $503,272.00 | |
| 4/7/2015 | B Lynne Parshall | COO | Sell | 5,565 | $63.07 | $350,984.55 | |
| 4/7/2015 | Stanley T Crooke | CEO | Sell | 22,377 | $63.07 | $1,411,317.39 | |
| 3/24/2015 | C Frank Bennett | SVP | Sell | 15,000 | $70.61 | $1,059,150.00 | |
| 3/19/2015 | Elizabeth L Hougen | CFO | Sell | 10,000 | $73.33 | $733,300.00 | |
| 3/19/2015 | Patrick R O'neil | SVP | Sell | 30,525 | $74.85 | $2,284,796.25 | |
| 3/2/2015 | Joseph H Wender | Director | Sell | 7,000 | $65.97 | $461,790.00 | |
| 1/27/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $72.93 | $802,230.00 | |
| 1/16/2015 | B Lynne Parshall | COO | Sell | 4,093 | $67.96 | $278,160.28 | |
| 1/16/2015 | Elizabeth L Hougen | CFO | Sell | 1,291 | $67.96 | $87,736.36 | |
| 1/16/2015 | Richard S Geary | SVP | Sell | 1,543 | $67.96 | $104,862.28 | |
| 1/16/2015 | Stanley T Crooke | CEO | Sell | 9,054 | $67.96 | $615,309.84 | |
| 1/9/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $73.57 | $809,270.00 | |
| 1/7/2015 | Stanley T Crooke | CEO | Sell | 22,000 | $67.04 | $1,474,880.00 | |
| 1/2/2015 | B Lynne Parshall | COO | Sell | 11,200 | $62.12 | $695,744.00 | |
| 1/2/2015 | Patrick R O'neil | SVP | Sell | 1,500 | $62.12 | $93,180.00 | |
| 12/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $51.21 | $76,815.00 | |
| 11/3/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | |
| 10/30/2014 | B Lynne Parshall | COO | Sell | 11,071 | $45.12 | $499,523.52 | |
| 10/23/2014 | Stanley T Crooke | CEO | Sell | 14,600 | $42.22 | $616,412.00 | |
| 10/3/2014 | Stanley T Crooke | CEO | Sell | 36,000 | $38.52 | $1,386,720.00 | |
| 10/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $38.04 | $57,060.00 | |
| 10/1/2014 | Stanley T Crooke | CEO | Sell | 20,000 | $37.91 | $758,200.00 | |
| 8/27/2014 | C Frank Bennett | SVP | Sell | 5,000 | $40.53 | $202,650.00 | |
| 8/13/2014 | Stanley T Crooke | CEO | Sell | 15,500 | $35.45 | $549,475.00 | |
| 8/12/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.00 | $52,500.00 | |
| 8/1/2014 | Stanley T Crooke | CEO | Sell | 16,000 | $30.53 | $488,480.00 | |
| 7/31/2014 | Brett P Monia | SVP | Sell | 79 | $31.50 | $2,488.50 | |
| 7/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.33 | $52,995.00 | |
| 7/1/2014 | Stanley T Crooke | CEO | Sell | 17,500 | $35.57 | $622,475.00 | |
| 6/23/2014 | C Frank Bennett | SVP | Sell | 11,200 | $36.78 | $411,936.00 | |
| 6/19/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $35.10 | $386,100.00 | |
| 6/10/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $33.46 | $368,060.00 | |
| 6/2/2014 | Frederick T Muto | Director | Sell | 10,000 | $28.59 | $285,900.00 | |
| 4/2/2014 | Stanley Crooke | CEO | Sell | 8,800 | $43.65 | $384,120.00 | |
| 1/30/2014 | B Lynne Parshall | COO | Sell | 89,510 | $49.49 | $4,429,849.90 | |
| 1/24/2014 | Joseph Klein III | Director | Sell | 10,313 | $48.66 | $501,830.58 | |
| 1/22/2014 | Joseph Wender | Director | Sell | 10,000 | $50.98 | $509,800.00 | |
| 1/22/2014 | Richard Geary | SVP | Sell | 22,200 | $50.05 | $1,111,110.00 | |
| 1/16/2014 | B Lynne Parshall | COO | Sell | 1,641 | $47.08 | $77,258.28 | |
| 1/16/2014 | Stanley Crooke | CEO | Sell | 3,527 | $47.08 | $166,051.16 | |
| 1/8/2014 | Richard Geary | SVP | Sell | 15,000 | $40.45 | $606,750.00 | |
| 1/8/2014 | Stanley Crooke | CEO | Sell | 12,500 | $40.05 | $500,625.00 | |
| 1/2/2014 | Stanley Crooke | CEO | Sell | 31,500 | $39.35 | $1,239,525.00 | |
| 12/26/2013 | B Lynne Parshall | COO | Sell | 37,811 | $40.91 | $1,546,848.01 | |
| 12/24/2013 | B Lynne Parshall | COO | Sell | 70,000 | $41.49 | $2,904,300.00 | |
| 12/20/2013 | Joseph Wender | Director | Sell | 19,731 | $39.58 | $780,952.98 | |
| 12/5/2013 | C Frank Bennett | SVP | Sell | 10,000 | $39.92 | $399,200.00 | |
| 11/26/2013 | Joseph Wender | Director | Sell | 10,000 | $36.63 | $366,300.00 | |
| 9/20/2013 | B Lynne Parshall | COO | Sell | 90,000 | $35.43 | $3,188,700.00 | |
| 9/20/2013 | Brett Monia | SVP | Sell | 68,281 | $34.21 | $2,335,893.01 | |
| 9/20/2013 | Stanley Crooke | CEO | Sell | 58,740 | $35.19 | $2,067,060.60 | |
| 9/19/2013 | C Frank Bennett | SVP | Sell | 10,000 | $35.02 | $350,200.00 | |
| 9/11/2013 | B Lynne Parshall | COO | Sell | 63,505 | $31.04 | $1,971,195.20 | |
| 9/9/2013 | C Frank Bennett | SVP | Sell | 10,000 | $30.23 | $302,300.00 | |
| 9/4/2013 | Patrick R O'neil | SVP | Sell | 2,500 | $27.09 | $67,725.00 | |
| 8/26/2013 | Brett Monia | SVP | Sell | 2,909 | $25.58 | $74,412.22 | |
| 8/9/2013 | Joseph Klein III | Director | Sell | 18,750 | $28.22 | $529,125.00 | |
| 7/23/2013 | Stanley T Crooke | COO | Sell | 11,500 | $30.00 | $345,000.00 | |
| 7/22/2013 | Stanley T Crooke | CEO | Sell | 62,200 | $30.50 | $1,897,100.00 | |
| 7/17/2013 | Stanley T Crooke | CEO | Sell | 49,300 | $33.12 | $1,632,816.00 | |
| 7/12/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $31.75 | $2,857,500.00 | |
| 7/11/2013 | Richard S Geary | SVP | Sell | 9,000 | $31.90 | $287,100.00 | |
| 7/9/2013 | Richard S Geary | SVP | Sell | 66,163 | $30.03 | $1,986,874.89 | |
| 7/9/2013 | Stanley T Crooke | CEO | Sell | 109,172 | $26.69 | $2,913,800.68 | |
| 7/3/2013 | Richard S Geary | SVP | Sell | 5,000 | $29.02 | $145,100.00 | |
| 7/1/2013 | Stanley T Crooke | CEO | Sell | 50,683 | $27.65 | $1,401,384.95 | |
| 6/26/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $26.73 | $2,405,700.00 | |
| 6/25/2013 | Richard S Geary | SVP | Sell | 47,049 | $26.20 | $1,232,683.80 | |
| 6/20/2013 | Joseph H Wender | Director | Sell | 5,447 | $20.93 | $114,005.71 | |
| 6/11/2013 | Brett P Monia | SVP | Sell | 9,375 | $23.76 | $222,750.00 | |
| 5/30/2013 | Frederick T Muto | Director | Sell | 10,000 | $21.96 | $219,600.00 | |
| 1/16/2013 | Stanley T Crooke | CEO | Sell | 1,460 | $14.00 | $20,440.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ionis Pharmaceuticals (NASDAQ:IONS)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
| Source: |
|
| Date | Headline |
|---|
 | Voyager Therapeutics (VYGR) & Ionis Pharmaceuticals (IONS) Financial Comparison
www.americanbankingnews.com - September 20 at 4:14 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM |
| Analyzing Brainstorm Cell Therapeutics (BCLI) and Ionis Pharmaceuticals (IONS)
www.americanbankingnews.com - September 17 at 2:31 AM |
 | Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada - Nasdaq
www.nasdaq.com - September 12 at 4:41 PM |
 | Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
finance.yahoo.com - September 12 at 4:41 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 12 at 2:50 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - September 12 at 11:22 AM |
 | Ionis Pharma (IONS) Reports New Data from Clinical Program for IONIS-STAT3-2.5Rx (AZD9150) at ESCO 2017
www.streetinsider.com - September 12 at 1:43 AM |
| Ionis Pharma (IONS) Reports New Data from Clinical Program for IONIS-STAT3-2.5Rx (AZD9150) at ESCO 2017 - StreetInsider.com
www.streetinsider.com - September 11 at 6:12 AM |
| New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi
finance.yahoo.com - September 11 at 6:12 AM |
| Ionis Pharmaceuticals, Inc. (IONS) Receives New Coverage from Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:16 PM |
 | NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted
www.rttnews.com - September 8 at 1:19 AM |
| Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells 1,000 Shares of Stock
www.americanbankingnews.com - September 7 at 10:24 PM |
 | Breaking Down Barclays' New Bullish Calls On Biotech - Benzinga
www.benzinga.com - September 7 at 8:16 PM |
| Today's Research Reports on Trending Tickers: Nektar Therapeutics and Ionis Pharmaceuticals Inc.
finance.yahoo.com - September 2 at 12:13 AM |
| Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : September 1, 2017
finance.yahoo.com - September 2 at 12:13 AM |
 | Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the US FDA - GlobeNewswire (press release)
globenewswire.com - September 1 at 1:00 AM |
| Technology Platforms and Research Programs Drive LGND’s Partnerships
finance.yahoo.com - August 31 at 7:58 PM |
| Ionis Pharma (IONS) Earns $40M Milestone from Biogen for SPINRAZA
www.streetinsider.com - August 31 at 6:15 AM |
| Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
finance.yahoo.com - August 31 at 6:15 AM |
| $129.33 Million in Sales Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter
www.americanbankingnews.com - August 29 at 3:12 PM |
 | Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation - PR Newswire (press release)
www.prnewswire.com - August 25 at 10:26 PM |
| Must-Know Developments for Ionis Pharmaceuticals
finance.yahoo.com - August 25 at 4:43 PM |
| How Akcea Therapeutics’ Volanesorsen Performed in 2Q17
finance.yahoo.com - August 25 at 7:09 AM |
| What’s Ionis Pharmaceuticals’ Valuation?
finance.yahoo.com - August 24 at 8:02 AM |
| Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation
finance.yahoo.com - August 24 at 8:02 AM |
| What Drove Ionis’s Revenues in 2Q17?
finance.yahoo.com - August 24 at 8:02 AM |
| Ionis Pharmaceuticals, Inc. (IONS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 18 at 2:42 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Receives New Coverage from Analysts at Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM |
| Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review
finance.yahoo.com - August 16 at 4:43 PM |
| Ionis Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IONS) : August 15, 2017
finance.yahoo.com - August 16 at 1:42 AM |
 | Alnylam Pharmaceuticals results: The only number that really matters - Motley Fool
www.fool.com - August 15 at 3:58 AM |
 | Ionis Absorbs Glaxo Rare Disease Cull - Seeking Alpha
seekingalpha.com - August 15 at 3:58 AM |
| See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
finance.yahoo.com - August 14 at 10:58 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Given New $69.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - August 14 at 10:34 PM |
| Ionis Pharmaceuticals' (NASDAQ:IONS) "Buy" Rating Reaffirmed at Laidlaw
www.americanbankingnews.com - August 14 at 9:52 PM |
| Short Interest in Ionis Pharmaceuticals, Inc. (IONS) Drops By 15.8%
www.americanbankingnews.com - August 12 at 1:44 AM |
| Ionis Pharma (IONS) Says it Retained All Rights to Inotersen and IONIS-FB-LRx
www.streetinsider.com - August 11 at 11:51 PM |
| Ionis to Independently Advance Inotersen and IONIS-FB-L Rx
finance.yahoo.com - August 11 at 11:51 PM |
| Q3 2017 EPS Estimates for Ionis Pharmaceuticals, Inc. (IONS) Boosted by Jefferies Group
www.americanbankingnews.com - August 11 at 9:12 AM |
| IONS Crosses Below Key Moving Average Level
www.nasdaq.com - August 10 at 9:44 PM |
| Zacks: Analysts Anticipate Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Will Announce Quarterly Sales of $101.60 Million
www.americanbankingnews.com - August 10 at 9:52 AM |
| Ionis Provides Improved 2017 Guidance Following Strong Financial Performance
finance.yahoo.com - August 9 at 12:39 AM |
| Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings
finance.yahoo.com - August 9 at 12:39 AM |
| Edited Transcript of IONS earnings conference call or presentation 8-Aug-17 3:30pm GMT
finance.yahoo.com - August 9 at 12:39 AM |
| Ionis Pharmaceuticals' (IONS) CEO Stanley Crooke on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 7:37 PM |
| Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings - Nasdaq
www.nasdaq.com - August 8 at 7:37 PM |
| Ionis Pharmaceuticals reports 2Q loss
finance.yahoo.com - August 8 at 7:37 PM |
| Zacks: Brokerages Expect Ionis Pharmaceuticals, Inc. (IONS) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - August 8 at 4:28 PM |
| Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Posts Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - August 8 at 9:58 AM |
Ionis Pharmaceuticals (IONS) Chart for Thursday, September, 21, 2017
